A question on #Nabiximols #MultipleSclerosis tabled by Yasmin Qureshi on 04-09-2026 has been answered by Mr James Frith. https://questions-statements.parliament.uk/written-questions/detail/2026-09-04/27240
@dhsc-answers.bsky.social
@dhsc-answers.bsky.socialA question on #Nabiximols #MultipleSclerosis tabled by Yasmin Qureshi on 04-09-2026 has been answered by Mr James Frith. https://questions-statements.parliament.uk/written-questions/detail/2026-09-04/27240
@dhsc-answers.bsky.socialA question on #Nabiximols #MultipleSclerosis tabled by Yasmin Qureshi on 04-09-2026 has been answered by Mr James Frith. https://questions-statements.parliament.uk/written-questions/detail/2026-09-04/27242
@biorasi.bsky.socialNext week on the @biorasi.bsky.social Few & Far Between podcast!
Host Melissa Alesse welcomes Jason Tardio, CEO of #ImmunicTherapeutics, to the show.
Join us as we explore treatments for #multiplesclerosis and why great leaders listen as much as they speak.
See you then!
@gregoryai.bsky.socialBrain Res. 2026 Sep 10:150544. doi: 10.1016/j.brainres.2026.150544. Online ahead of print. ABSTRACT Neuroinflammation driven by autoreactive T cells and activated glial populations underlies the pathogenesis of multiple sclerosis (MS), y...
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky
@epigenometech.bsky.socialEpigenetics Update - A Lactate–H4K12la–HDAC1 epigenetic axis governs microglial state transitions during experimental autoimmune encephalomyelitis in female mice u.epigenome.us/jLW1B75s
#Epigenetics #Chromatin #MultipleSclerosis #H4K12la #HDAC #Microglia
---
Gain hi-res insight; epigenometech.com
@shannonsindorf.bsky.social
@kevjbyrne.bsky.socialA fitting and to one heck of a Garage Dayz start in September! #NeverStopNeverQuitForThem #MultipleSclerosis #MS #nationalmssociety #CanYouTRK
@morethanms.bsky.social“That’s a lot of work for you” isn’t always a reason not to do it.
Sometimes I know it’ll cost me. I do it anyway because I like it.
I’m trying to live here, man. Not slowly give up everything that makes life mine.
@kevjbyrne.bsky.social22.57 miles, 1:24 hours – only 22 miles, but probably my most significant Garage Dayz to date! Definitely the most emotional. Don’t forget to check on your buddies today. #NeverStopNeverQuitForThem #MultipleSclerosis #WorldSuicidePreventionDay #VeteranSuicidePrevention #VetsReachOut
@allisonratkovich.bsky.socialI called it a diet. It was sepsis. New essay on what a decade of ignoring my body actually cost me — and the math I'm finally doing differently now that it nearly killed me. #multiplesclerosis #chronicillness #personalhealth #sepsis #pneumonia
@kevjbyrne.bsky.socialWhen life punches you square in the face, prioritize what matters then punch back! This is in support of World Suicide Prevention Day - #NeverStopNeverQuitForThem #MultipleSclerosis #WorldSuicidePreventionDay #VeteranSuicidePrevention #VetsReachOut
@joelenton.bsky.socialNew podcast interview out today telling my story to Epicca talks
@msnewstoday.bsky.socialTake a closer look: https://bit.ly/4gKQeQ3
Increased memory loss over time, known as accelerated long-term forgetting, is greater in people with MS than in healthy adults, per a study.
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) secures FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination in multiple sclerosis patients. Rodman & Renshaw initiates coverage with a Buy rating and $8 price target. #MultipleSclerosis #Biopharma
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class drug designed to protect and repair the myelin sheath rather than suppress the immune system. Wall Street responds with a new buy rating. #Biotech #MultipleSclerosis
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA clearance for its Lucid-MS IND application, paving the way for a phase 2 trial of a first-in-class MS drug targeting demyelination directly rather than suppressing the immune system. #Biopharma #MultipleSclerosis
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class drug designed to rebuild the myelin sheath in MS patients — a historic first for this mechanism. Nearly 2.9 million people worldwide could benefit. #MultipleSclerosis #Biotech
@newsramp.comQuantum BioPharma receives FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class drug designed to rebuild the myelin sheath in MS patients — a historic milestone in neurological therapeutics. #MultipleSclerosis #Biotech
@abudd.bsky.social